4D Molecular Therapeutics Inc. Common Stock (FDMT)
Stock · NASDAQ · Health Care
$12.15as of 10/16/2026
Price chart
Active signals
FDMT Signal Track Record
How signals performed across all stocks →What FDMT's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 36 | -4.0% | 39% | October 5, 2026 |
| Bollinger Band Breakout | 28 | -3.3% | 39% | August 14, 2026 |
| Bollinger Band Breakdown | 22 | -3.2% | 41% | May 18, 2026 |
| 200-Day Moving Average TouchActive now | 6 | +22.1% | 67% | July 28, 2026 |
| Any 20-session window (baseline) | -2.6% | 45% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About FDMT
4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States. The company's lead product candidate is 4D-150 for the treatment of retinal vascular diseases by providing multi-year sustained production of anti-VEGF from the…
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Employees
- 196
- Website
- 4dmoleculartherapeutics.com/
Fundamentals
- 1-day range
- $12.04$13.01
- Market cap
- $551.51M
- P/E (trailing)
- —
- P/E (forward)
- -3.14
- EPS (trailing)
- $-2.76
- Dividend yield
- —
- Beta
- 2.90
- Avg. volume
- 941.5K
How 4D Molecular Therapeutics Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Mar 18, 2026 · via SEC EDGAR / Finnhub
Forecasts
11 analyst ratings
4D Molecular Therapeutics Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- FDMT4D Molecular Therapeutics Inc. Common Stock$12.14▼ 5.67%Market cap $551.51MP/E —$6.96$16.93
- ZURAZura Bio Limited Class A Ordinary Shares$3.88▼ 9.35%Market cap $542.44MP/E —$3.15$7.44
- ARTVArtiva Biotherapeutics Inc. Common Stock$5.85▼ 3.47%Market cap $566.10MP/E —$2.75$14.53
- PRMEPrime Medicine Inc. Common Stock$3.47▼ 3.88%Market cap $532.82MP/E —$2.67$6.65
- TECXTectonic Therapeutic Inc. Common Stock$20.65▼ 3.05%Market cap $570.23MP/E —$14.6$39.53
- AUTLAutolus Therapeutics plc American Depositary Share$1.6▼ 6.98%Market cap $532.31MP/E —$1.18$2.58
- DNAGinkgo Bioworks Holdings Inc. Class A Common Stock$10.27▼ 12.67%Market cap $528.15MP/E —$5.37$18.22
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| FDMT 4D Molecular Therapeutics Inc. Common Stock | $551.51M | — | $12.14 | ▼ 5.67% | $6.96$16.93 |
| ZURA Zura Bio Limited Class A Ordinary Shares | $542.44M | — | $3.88 | ▼ 9.35% | $3.15$7.44 |
| ARTV Artiva Biotherapeutics Inc. Common Stock | $566.10M | — | $5.85 | ▼ 3.47% | $2.75$14.53 |
| PRME Prime Medicine Inc. Common Stock | $532.82M | — | $3.47 | ▼ 3.88% | $2.67$6.65 |
| TECX Tectonic Therapeutic Inc. Common Stock | $570.23M | — | $20.65 | ▼ 3.05% | $14.6$39.53 |
| AUTL Autolus Therapeutics plc American Depositary Share | $532.31M | — | $1.6 | ▼ 6.98% | $1.18$2.58 |
| DNA Ginkgo Bioworks Holdings Inc. Class A Common Stock | $528.15M | — | $10.27 | ▼ 12.67% | $5.37$18.22 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Chardan Capital Maintains Buy on 4D Molecular Therapeutics, Lowers Price Target to $25benzinga · 10/6/2026
- Chardan Capital Maintains Buy on 4D Molecular Therapeutics, Lowers Price Target to $25Benzinga · 10/6/2026
- 4DMT to Host Investor Day on October 21, 2026Yahoo · 10/5/2026
- This is the top biotech stock pick from B Riley SecuritiesYahoo · 9/29/2026
- 4D Molecular: Reiterate 'Buy' With Wet AMD 4D-150 Program On Track And Phase 3 DME Trial UnderwaySeekingAlpha · 9/29/2026
- B of A Securities Maintains Buy on 4D Molecular Therapeutics, Raises Price Target to $33Benzinga · 9/29/2026
- OCUL Stock Suffers Sharpest Drop Since February As KOD And FDMT Post Updates On Their Wet AMD DrugsYahoo · 9/28/2026
- 4DMT Advances 4D-150 into Phase 3 for Second Large Market Retina Indication with Initiation of 4SIGHT in DMEYahoo · 9/28/2026
- Scholastic Posts Downbeat Q1 Results, Joins Legacy Education, Zscaler And Other Big Stocks Moving Lower In Friday’s Pre-Market SessionBenzinga · 9/25/2026
Insider Activity
Insider Actions →- David Kirn · October 5, 2026 · Sale272 @ $13.61
- David Kirn · October 5, 2026 · Sale58.1K @ $12.92
- Scott Bizily · September 16, 2026 · Option Exercise1.6K @ $4.14
- Scott Bizily · September 16, 2026 · Sale1.6K @ $13.65
- David Kirn · September 14, 2026 · Sale58.3K @ $13.9
- Scott Bizily · September 1, 2026 · Option Exercise584 @ $6.49
- Scott Bizily · September 1, 2026 · Sale584 @ $14
- David Kirn · August 19, 2026 · Option Exercise50.0K @ $4.14
- David Kirn · August 19, 2026 · Sale25.9K @ $16.42
- David Kirn · August 19, 2026 · Sale43.1K @ $15.36
- Scott Bizily · August 17, 2026 · Option Exercise1.6K @ $4.14
- Scott Bizily · August 17, 2026 · Sale1.6K @ $12.2
- Scott Bizily · August 13, 2026 · Option Exercise1.6K @ $4.14
- Scott Bizily · August 13, 2026 · Sale1.6K @ $12
- David Kirn · August 4, 2026 · Sale26.8K @ $10.23
Institutional Ownership
March 31, 2026
- Total shares held
- 48.21M
- Total value held
- $447.40M
- Institutional holders
- 147
- Unknown5.25M
- Unknown5.05M
- Unknown4.21M
- Unknown4.15M
- Unknown3.65M
- Unknown2.88M
- Unknown2.71M
- Unknown2.00M
- Unknown1.61M
- Unknown1.43M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
FDMT listed in Benzinga pre-market movers
4D Molecular Therapeutics was mentioned in a Benzinga report on stocks moving lower in Friday’s pre-market session. The article grouped FDMT with other companies like Scholastic and Zscaler, noting a generally downbeat tone among legacy education and other large-cap names. This indicates the stock was part of a broader market movement rather than reacting to a company-specific announcement.
FDMT listed in Benzinga pre-market movers. 4D Molecular Therapeutics was mentioned in a Benzinga report on stocks moving lower in Friday’s pre-market session. The article grouped FDMT with other companies like Scholastic and Zscaler, noting a generally downbeat tone among legacy education and other large-cap names. This indicates the stock was part of a broader market movement rather than reacting to a company-specific announcement.